Xia Chen

Xia Chen

Auto-generated profile, based on publicly available information

Xia Chen

Department of Pharmacy, Affiliated Hospital 2 of Nantong University, and First People’s Hospital of Nantong City, Nantong, People’s Republic of China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2024 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
SRShujing Ren
Shujing Ren
YXYuhang Xu
Yuhang Xu
XDXingpeng Dong
Xingpeng Dong
QMQingxin Mu
Qingxin Mu
XCXia Chen
Xia Chen
GSGaoxing Su
Gaoxing Su
Rheumatoid arthritis (RA) is an autoimmune disease with multifactorial etiology and intricate pathogenesis. In RA, repeated monotherapy is frequently associated with inadequate efficacy, drug resistance, and severe side effects. Therefore, a shift has occurred in clinical practice toward combination therapy. However, conventional combination therapy encounters several hindrances, including low selectivity to arthritic joints, short half-lives, and varying pharmacokinetics among coupled drugs. Emerging nanotechnology offers an incomparable opportunity for developing advanced combination therapy against RA. First, it allows for co-delivering multiple drugs with augmented physicochemical properties, targeted delivery capabilities, and controlled release profiles. Second, it enables therapeutic nanomaterials development, thereby expanding combination regimens to include multifunctional nanomedicines. Lastly, it facilitates the construction of all-in-one nanoplatforms assembled with multiple modalities, such as phototherapy, sonodynamic therapy, and imaging. Thus, nanotechnology offers a promising solution to the current bottleneck in both RA treatment and diagnosis. This review summarizes the rationale, advantages, and recent advances in nano-empowered combination therapy for RA. It also discusses safety considerations, drug–drug interactions, and the potential for clinical translation. Additionally, it provides design tips and an outlook on future developments in nano-empowered combination therapy. The objective of this review is to achieve a comprehensive understanding of the mechanisms underlying combination therapy for RA and unlock the maximum potential of nanotechnology, thereby facilitating the smooth transition of research findings from the laboratory to clinical practice.

12 August 2022 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
PFPanFeng Feng
PanFeng Feng
LZLongXun Zhu
LongXun Zhu
JJJing Jie
Jing Jie
PYPengXiang Yang
PengXiang Yang
NSNan Sheng
Nan Sheng
XCXia Chen
Xia Chen

5 January 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LXLi Xin-Shuai
Li Xin-Shuai
JZJia-Qi Zhou
Jia-Qi Zhou
XCXiang-Fan Chen
Xiang-Fan Chen
XCXia Chen
Xia Chen
PFPanfeng Feng
Panfeng Feng
Objective: To evaluate the efficacy and safety of Ginkgolide Meglumine Injection (GMI) combined with Butylphthalide in the treatment of Acute Ischemic Stroke (AIS), and provide reference for rational clinical medication. Methods: PubMed, Embase, Web of science, CNKI, Wanfang, VIP and other databases were searched for published studies on the treatment of AIS with GMI combined with Butylphthalide in both Chinese and English. The search period was from the establishment of the database to July 2023. The included studies that met the inclusion criteria were analyzed using RevMan 5.3 software for Meta-analysis. Results: A total of 25 studies involving 2362 patients (experimental group = 1182, control group = 1180) were included. The results of meta-analysis showed that the overall effective rate of the experimental group was significantly higher than that of the control group [RR = 1.21, 95% CI (1.16, 1.26), P< 0.00001]. In addition, compared with the control group, the experimental group showed significant improvement in NIHSS score [SMD = -1.59, % CI (-2.00–1.18), P< 0.00001] and ADL score [SMD = 2.12, 95% CI (1.52, -2.72), P<0.00001], significant decrease in CRP [SMD = -2.24, 95% CI (-3.31, -1.18), P<0.0001] and TNF-α [SMD = -2.74, 95% CI (-4.45, -1.03), P< 0.005] levels, and improvement in plasma viscosity [SMD = -0.86, 95% CI (-1.07, -0.66), P< 0.00001]. However, the influence on homocysteine level remains inconclusive. Furthermore, there was no significant difference in the incidence of adverse reactions between the two groups [SMD = 0.95, 95% CI (0.71, 1.28), P> 0.05]. Conclusion: GMI combined with Butylphthalide shows good clinical application effects and good safety in the treatment of AIS. However, more large-sample, multicenter, randomized controlled are needed to confirm these findings.

1 January 2022 in General Physiology and Biophysics
Verified
Journal Article
Closed access
LTLian Tang
Lian Tang
PFPanfeng Feng
Panfeng Feng
YQYan Qi
Yan Qi
LHLei Huang
Lei Huang
XLXiuying Liang
Xiuying Liang
XCXia Chen
Xia Chen
TGFβ1 induces myofibroblast transdifferentiation via increasing Smad-mediated RhoGDI-RhoGTPase signaling

11 April 2023 in Archives of Gerontology and Geriatrics
Verified
Journal Article
Closed access
TMTongtong Miao
Tongtong Miao
JYJia Yu
Jia Yu
QSQian Shen
Qian Shen
GFGuijuan Feng
Guijuan Feng
HDHuan Ding
Huan Ding
XZXiao Wei Zheng
Xiao Wei Zheng

7 July 2025 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
PDF file
PFPanFeng Feng
PanFeng Feng
LZLongXun Zhu
LongXun Zhu
JJJing Jie
Jing Jie
PYPengXiang Yang
PengXiang Yang
NSNan Sheng
Nan Sheng
XCXia Chen
Xia Chen